Acquired by Roche Good Therapeutics was acquired by Roche in September 2022, indicating integration into a global pharma powerhouse with potential collaboration or licensing opportunities for their allosteric protein activity technology.

Strategic pivot Post acquisition, the business expanded into Bonum Therapeutics to apply the technology to additional products, suggesting open avenues for partner programs or co-development ventures.

Early-stage funding Historically raised multiple rounds including seed and Series A/B totaling notable funds, signaling a credible technology risk profile and readiness for pharma partners to engage in later-stage development or milestone-based collaborations.

Cancer focus Public notes highlight development of medicines for cancer and other diseases, offering sales opportunities with oncology and translational research units seeking targeted, environment-responsive therapeutics.

Limited internal scale Current employee count and concentrated technology focus imply a need for external collaborations, contract research, or licensing deals to accelerate development and commercialization with larger organizations.